Article Cited by others


Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities

Gupta Sandeep Kumar, Nayak Roopa Prasad

Year : 2014| Volume: 5| Issue : 2 | Page no: 88-92

   This article has been cited by
1 Drug repositioning, a new alternative in infectious diseases
Marissa Bolson Serafin,Rosmari Hörner
The Brazilian Journal of Infectious Diseases. 2018; 22(3): 252
[Pubmed]  [Google Scholar] [DOI]
2 Extended infusion—putting the benefit into context
Markus Zeitlinger
The Lancet Infectious Diseases. 2018; 18(4): 380
[Pubmed]  [Google Scholar] [DOI]
3 Identifying Off-Label Prescriptions Through Data Mining in Danish Community Pharmacy Servers: An Exploratory Study on Desmopressin, Diclofenac, Fucidin, Mirtazapine and Quetiapine
Monika Andrulyte,Ole Jannik Bjerrum
Basic & Clinical Pharmacology & Toxicology. 2018;
[Pubmed]  [Google Scholar] [DOI]
4 Knowledge and attitudes of patients in primary care on off-label treatment
Mario Curkovic,Dražen Gorjanski
International Journal of Risk & Safety in Medicine. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
5 Repurposing Drugs in Oncology: Next Steps
Ciska Verbaanderd,Lydie Meheus,Isabelle Huys,Pan Pantziarka
Trends in Cancer. 2017;
[Pubmed]  [Google Scholar] [DOI]
6 Off-label use of medicines: The need for good practice guidelines
Marc Dooms,James Killick
International Journal of Risk & Safety in Medicine. 2017; 29(1-2): 17
[Pubmed]  [Google Scholar] [DOI]
7 Repurposing N,Nć-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent inhibitors of cholinesterases
Anne Loesche,Jana Wiese,Sven Sommerwerk,Vivienne Simon,Wolfgang Brandt,René Csuk
European Journal of Medicinal Chemistry. 2017; 125: 430
[Pubmed]  [Google Scholar] [DOI]
8 PMTDS: a computational method based on genetic interaction networks for Precision Medicine Target-Drug Selection in cancer
Varshini Vasudevaraja,Jamie Renbarger,Ridhhi Girish Shah,Garrett Kinnebrew,Murray Korc,Limei Wang,Yang Huo,Enze Liu,Lang Li,Lijun Cheng
Quantitative Biology. 2017;
[Pubmed]  [Google Scholar] [DOI]
9 Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
Aaron S. Kesselheim,Carolyn L. Treasure,Steven Joffe
PLOS Medicine. 2017; 14(1): e1002190
[Pubmed]  [Google Scholar] [DOI]
10 Off-label use of orphan medicinal products: a Belgian qualitative study
Marc Dooms,David Cassiman,Steven Simoens
Orphanet Journal of Rare Diseases. 2016; 11(1)
[Pubmed]  [Google Scholar] [DOI]
11 Drotaverine - a Concealed Cytostatic!
Ioana Z. Pavel,Lucie Heller,Sven Sommerwerk,Anne Loesche,Ahmed Al-Harrasi,René Csuk
Archiv der Pharmazie. 2016;
[Pubmed]  [Google Scholar] [DOI]
12 After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
Tim K. Mackey,Bryan A. Liang
Mayo Clinic Proceedings. 2016;
[Pubmed]  [Google Scholar] [DOI]
13 Prescribing practice and off-label use of psychotropic medications in post-acute brain injury rehabilitation centres: A cross-sectional survey
Federica Edith Pisa,Giorgia Cosano,Manuela Giangreco,Tullio Giorgini,Emanuele Biasutti,Fabio Barbone
Brain Injury. 2015; 29(4): 508
[Pubmed]  [Google Scholar] [DOI]


Read this article